Identifying newly approved medications in Medicare claims data: A case study using tocilizumab

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 11, 2013, Pages 1214-1221

  Curtis, Jeffrey R ^a   Xie, Fenglong ^a   Chen, Rui ^c   Chen, Lang ^a   Kilgore, Meredith L ^c   Lewis, James D ^b   Yun, Huifeng ^a,c   Zhang, Jie ^c   Wright, Nicole C ^c   Delzell, Elizabeth ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biologics; Certolizumab; Denosumab; Linkage; Medicare; Part D; Pharmacoepidemiology; Registry; Rheumatoid arthritis; Tocilizumab

Indexed keywords

TOCILIZUMAB;

ALGORITHM; ARTICLE; DRUG APPROVAL; EXTERNAL VALIDITY; MEDICARE; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

BIOLOGICS; CERTOLIZUMAB; DENOSUMAB; LINKAGE; MEDICARE; PART D; PHARMACOEPIDEMIOLOGY; REGISTRY; RHEUMATOID ARTHRITIS; TOCILIZUMAB;

ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CLINICAL CODING; COHORT STUDIES; DATABASES, FACTUAL; DRUG APPROVAL; HUMANS; INJECTIONS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICARE; PHARMACOEPIDEMIOLOGY; REGISTRIES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84886281754     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3475     Document Type: Article

References (8)

1. DiMartino LD, Curtis LH, Williams RL, et al. Using medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. Food Drug Law J 2008; 63(4): 891-900.
2. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58(5):1299-1309.
3. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html.
4. Tocilizumab package insert.
5. Curtis JR, Jain A, Askling J, Bridges SL, Jr., Carmona L, Dixon W, et al.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40(1): 2-14 e1.
6. Kremer JM. The CORRONA database. Autoimmun Rev 2006; 5(1): 46-54.
7. Curtis JR, Chen L, Beukelman T, Bharat A, Xie F, Saag KG, et al. Methods To Link a National Arthritis Cohort with Medicare Administrative Claims Data. International Society of Pharmacoepidemiology 2012:Barcelona, Spain.
8. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 2012; 64(7): 1054-1060.